JP2023503868A5 - - Google Patents
Info
- Publication number
- JP2023503868A5 JP2023503868A5 JP2022528714A JP2022528714A JP2023503868A5 JP 2023503868 A5 JP2023503868 A5 JP 2023503868A5 JP 2022528714 A JP2022528714 A JP 2022528714A JP 2022528714 A JP2022528714 A JP 2022528714A JP 2023503868 A5 JP2023503868 A5 JP 2023503868A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- structural unit
- complex according
- receptor
- protein complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944203P | 2019-12-05 | 2019-12-05 | |
| US62/944,203 | 2019-12-05 | ||
| PCT/US2020/063214 WO2021113577A1 (en) | 2019-12-05 | 2020-12-04 | Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023503868A JP2023503868A (ja) | 2023-02-01 |
| JP2023503868A5 true JP2023503868A5 (cg-RX-API-DMAC7.html) | 2023-12-08 |
Family
ID=76222692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528714A Pending JP2023503868A (ja) | 2019-12-05 | 2020-12-04 | インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220402988A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069725A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023503868A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115315434A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021113577A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| JP2023540629A (ja) * | 2020-09-16 | 2023-09-25 | ベイジーン リミテッド | インターロイキン１５構築物及び使用方法 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| US20230035308A1 (en) * | 2021-07-02 | 2023-02-02 | Aetio Biotherapy, Inc. | Activatable monomeric cytokine-single chain (sc) fc fusion proteins and uses thereof |
| CA3238283A1 (en) * | 2021-11-15 | 2023-05-19 | Yangxin Fu | Fusion protein construct taking interleukin 15 as active ingredient and use thereof |
| JP2025507733A (ja) * | 2022-02-28 | 2025-03-21 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用 |
| EP4695281A1 (en) * | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120936384A (zh) * | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2025113255A1 (zh) * | 2023-11-28 | 2025-06-05 | 北京昌平实验室 | 抗肿瘤抗体与白介素15前体的双功能复合分子及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2011450C (en) * | 1989-03-07 | 2002-06-04 | Tadatsugu Taniguchi | Recombinant b-chain of the il-2 receptor |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| US8507222B2 (en) * | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| PT3444271T (pt) * | 2013-08-08 | 2022-01-05 | Inst Nat Sante Rech Med | Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa |
| WO2019006472A1 (en) * | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| CN110437339B (zh) * | 2018-05-04 | 2021-08-13 | 免疫靶向有限公司 | 一种以白介素15为活性成分的融合蛋白型药物前体 |
| US20220002370A1 (en) * | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| CA3141626A1 (en) * | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
-
2020
- 2020-12-04 WO PCT/US2020/063214 patent/WO2021113577A1/en not_active Ceased
- 2020-12-04 JP JP2022528714A patent/JP2023503868A/ja active Pending
- 2020-12-04 EP EP20895945.2A patent/EP4069725A4/en active Pending
- 2020-12-04 US US17/777,088 patent/US20220402988A1/en active Pending
- 2020-12-04 CN CN202080095025.8A patent/CN115315434A/zh active Pending